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Overview/Abstract
Medications are developed by the pharmaceutical industry starting with the discovery
phase, proceeds to preclinical trials, moves into clinical trials (progressing from Phase I
to Phase III), and if the data are positive, may lead to Food and Drug Administration
(FDA) approval. Once approved, post-marketing surveillance for safety is required as
long as the drug is marketed to consumers. This phase may also include clinical trial
Phase IV studies if additional safety testing is required. This process usually takes
between ten to fifteen years, with clinical development taking seven to ten years of that
time (1). Clinical development can be facilitated by a clinical development Project
Management Office (PMO) at pharmaceutical companies. Clinical development PMOs
provide value by establishing processes that can be universally adopted by the
pharmaceutical industry. This can help simplify product development, and as a result,
accelerate time to market. Clinical development project management is a relatively new
field in the pharmaceutical industry, and there are few publications and literary reviews
regarding standardized best practices, current best practices, and potential best
practices for clinical development.
Decreasing the time it takes a drug to reach market can help patients live longer and/or
improve their quality of life. Time to market is often driven by the time it takes to test the
product in clinical settings. This thesis is focused on analyzing the clinical development
project management practices in order to reduce the time to market. The goals of this
project were to identify best practices in clinical development project management,
compile a reference standard, develop a rubric, evaluate the rubric on a comparator
company, and make a recommendation regarding actions required for the comparator
company to achieve the reference standard.
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1. Introduction
The beginning of the regulation of the pharmaceutical industry can be traced back to
1938 when Congress passed the Federal Food, Drug, and Cosmetic Act (FDCA) law.
The external landscape of the pharmaceutical industry and drug regulations have made
big strides in the past 50-100 years due to various tragedies of the time. This included
one of the first mass-deaths reported of over 100 patients due to a sulfanilamide
medication used to treat streptococcal infections. The revised formulation used
diethylene glycol (antifreeze) to dissolve the drug. This forced legislation to initially
regulate safety (2). Regulations later followed regarding drug quality and efficacy. In
order to bring a product to market, companies must first seek approval for testing in
clinical trials (supported by scientific data), and if the results indicate a therapeutic
benefit that outweighs any associated risks, then the company may seek approval to
market the product.
1.1

Drug Definition

The term pharmaceutical products refers to medicines or drugs. According to the World
Health Organization (WHO), it is important that prescribed products are of good quality,
safe, effective and prescribed and used rationally (3). The Food and Drug Administration
(FDA) defines drugs as any product that is intended to affect body structure or function
for the purpose of diagnosis, treatment or prevention of disease (4).
Pharmaceutical products can be classified as small molecules (chemical compounds),
generics (non-branded version of a small molecule), biologics (produced by or part of a
living organism) or biosimilars (non-branded version of an existing biologic). These
products may also be available either as prescription only or over-the-counter (OTC),
and may vary in the formulation (e.g., liquid or tablet) and routes of administration (e.g.,
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oral, nasal, or transdermal). Regardless of the classification or formulation, the approval
process by the FDA is the same.
The development of small molecule drugs for treating and preventing disease played an
important role in the practice of medicine. The history of small molecules spans
thousands of years with the use of naturally occurring extracts for medicinal purposes
(e.g., aspirin), to present day de novo synthetic organic molecules for drug development
(e.g., statins). This has contributed to the improvement of health and increased life
expectancy (5).
Generic drugs emerged in the United States in 1984 with the Drug Price Competition
and Patent Term Restoration Act, also known as the Hatch-Waxman Act, which changed
the pharmaceutical field by making it easier for generic drugs to enter the market (6).
The FDA states that a generic drug product must be comparable to the reference drug in
terms of strength, performance, safety, quality, method of administration, and dosage
form. It is essential that the generic drug have the same intended use as the reference
drug (7).
The regulation of biological products began with the Biologics Control Act of 1902.
Unlike traditional chemical manufacturing of drugs, biological products are isolated from
living organisms. Biological products include vaccines, blood derivatives, and gene
therapy products amongst others. Biologics are used in the treatment of cancer and
other diseases (8). The most recent development is biosimilars, which are developed
from living cells through highly complex manufacturing processes, but “similar” to
another biologic already approved by the FDA. An example of a biosimilar is Zarxio
(Filgrastim-sndz) (9) which was FDA approved in 2015 and is analogous to Neupogen
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(Filgrastim). Both drugs are prescribed to cancer patients following chemotherapy to
help decrease the risk of developing neutropenia.
1.2

FDA Drug Approval Process

FDA ensures that the drugs on market, whether brand name or generic, are safe and
effective, and that the health benefits outweigh the risks. The process begins at the
discovery phase, proceeds to preclinical trials, moves into clinical trials (progressing
from Phase I to Phase III), and if the data are positive, may lead to FDA approval. The
life cycle management stage includes post-marketing surveillance for safety as long as
the drug is marketed to consumers. Post-marketing may also include clinical trial Phase
IV studies if additional safety testing is required. The discovery phase involves
investigation of thousands of compounds as potential drug candidates. Once a
promising compound is found, experiments are conducted to gather initial information on
a number of factors, such as how it is metabolized, the potential benefits, dosage,
administration, side effects, other drug interactions and effectiveness. Following
discovery, further information on these factors are gathered through preclinical trials,
which involve both in vitro and in vivo animal research to evaluate the new drug’s safety
(e.g., toxicity) and efficacy. Following the data obtained from these tests, an
Investigational New Drug (IND) application is submitted to the FDA that includes
information on the drug composition, manufacturing, and clinical trial plan. The FDA
reviews the IND to verify that the proposed studies, known as clinical trials, focus to
ensure clinical trial subject safety. The FDA also verifies that there is informed consent
and that human subject protections are in place prior to initiation of clinical trials. If the
FDA feels that these criteria are met, the drug under investigation then moves to the
clinical stage where the drug sponsor’s clinical trials are divided into Phases I, II, and III.
In clinical trial Phase I, the focus is evaluating the safety of the drug, and traditionally
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involves approximately 20-80 healthy volunteers with the goal of the identifying the
drug’s side effects, and evaluating how the drug is absorbed, distributed, metabolized
and excreted from the body. If the data captured in clinical trial Phase I are positive, the
drug transitions into clinical trial Phase II, where traditionally the number of subjects
increases into the hundreds. The focus of clinical trial Phase II is learning more about
the safety of the drug, including the maximum tolerated dose, and looking for initial
efficacy signs in people who have the particular condition or disease. At the conclusion
of clinical trial Phase II, assuming the data are positive, the FDA and drug sponsors
discuss how the clinical trial Phase III studies will be designed and completed. In clinical
trial Phase III, the patient numbers traditionally move into the thousands and the primary
focus is to evaluate efficacy, along with continual assessment of safety. Following this
phase, a meeting between the FDA and drug sponsor occurs before the submission of a
New Drug Application (NDA). The NDA filing is requested by the drug sponsor to gain
approval from the FDA to market the drug in the United States, supported by all the data
gathered to date as outlined above. Following the receipt of the NDA, the FDA has 60
days to evaluate whether the applicant has provided the information required for FDA
review. If sufficiently complete, the FDA review team evaluates the sponsor’s data on
drug safety and effectiveness. As part of the review process, the FDA will inspect the
manufacturing facility(ies) and a subset of the clinical and nonclinical testing sites. If the
FDA doesn’t evaluate the drug’s benefits outweigh the risks, they will issue a “Complete
Response Letter”, which means that product cannot be sold in the US. The company
can then choose to conduct further testing or not pursue the product at all. If the FDA
deems that the benefits outweigh the risks, the FDA will negotiate the exact drug label
with the sponsor to ensure important information is communicated to health care
professionals and patients, and officially approve the product. As it is not possible to
predict what happens after the drug is on the market, post-market surveillance of safety
4

is required. Further studies (clinical trial Phase IV) may also be required to also evaluate
specific safety questions. The drug sponsor is also required to submit periodic safety
updates to the FDA throughout the drug’s marketed life. In addition to sponsor safety
reporting requirements, the FDA also provides a mechanism for physicians and patients
to voluntarily report adverse events. Should post-marketing safety analysis identify new
safety risks, product availability can be restricted (e.g., through a restricted access
program, also known as Risk Evaluation and Mitigation Strategy or REMS) or in rarer
cases, the drug can be withdrawn from the market.
1.3

Time to Market

In 2013, drug discovery products accounted for about 5,000-10,000 of potential products
being developed. Of those potential products, only between 2.5% to 5% move to
preclinical. Less than one-half of one percent of products investigated in preclinical
stages are approved. The average time from discovery to market for drugs is ten to
fifteen years, with a hefty portion of that time spent in clinical trials (six to seven years;
Table 1).
Table 1: Average time from discovery to market

Products in
stage
Duration

Drug
Discovery

Preclinical

Clinical Trials

Approval and
Launch

5,000 – 10,000

250

5

1

6-7 Years

0.5 – 2 Years

3-6 Years

Source: PhRMA, 2013

The top five fastest drug developers average 3.9 to 4.6 years in clinical development
Table 2 (1). The fastest developer (Abbott) leads the median clinical trial duration with 47
months as opposed to the fifth fastest developer (BioMarin) at 55 months, almost a halfyear difference. Conversely, BioMarin leads with the shortest NDA approval median
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duration (6 months), which is due to shorter review times for orphan drugs in comparison
to other drugs.
Table 2: 2014 Fastest drug developers

Janssen
(J&J)
Abbott
Sanofi
Shire
BioMarin

Median clinical
duration (in months)
47

Median NDA approval
duration (in months)
10

Total median duration
(in months)
57

47
51
55
55

9
13
19
6

56
64
73
61

Source: CenterWatch, 2013

Pharmaceutical companies face challenges through the lengthy drug development
process (Figure 1). Not only is a pharmaceutical company looking to deliver a product
quicker, they are often competing in a race against other companies to be the first in the
market. This requires efficiency throughout the organization. The complex product
development process from molecule to product involves the management of many
business processes such as manufacturing, regulatory strategy, and clinical
development.
The analysis of best practices in pharmaceutical industry, specifically in clinical
development, where the most time is spent, will help identify standard practices for
efficient drug development.
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Figure 1: Drug development lifecycle
The drug development lifecycle starts with the discovery phase, proceeds to preclinical trials, and
moves into clinical trials, progressing from Phase I to Phase III, and depending on the data, may
lead to FDA approval. The life cycle management stage includes post-marketing surveillance for
safety as long as the drug is marketed to consumers. Post-marketing may also include clinical
trial Phase IV studies if additional safety testing is required.

1.4

Project Management Role in Pharma

Project management has been known to drive success in industries such as information
technology (IT) and construction/engineering (10). In the last decade, project
management has been adopted by some pharmaceutical sectors, e.g., devices, but not
holistically (5).
There are few publications and literary reviews regarding standardized best practices,
current best practices, and potential novel best practices for clinical development project
management in pharmaceuticals (11). Furthering the knowledge in this area is warranted
and would facilitate bringing products to patients sooner without sacrificing quality.
2

Objectives and Strategy

The specific aims of the project were:
I.

Establish a reference standard for best practices (Phase I)

II.

Develop an assessment methodology (rubric) for the Project Management
Offices to the reference as standard (Phase I)

III.

Evaluate the rubric (Phase II) using a comparator company

7

IV.

Make recommendations for how the comparator company could achieve the
reference standard (Phase II)

This research study involved a three-fold approach: study design, qualitative exploratory
research (Phase I), and quantitative confirmatory research (Phase II).
3

Research Design and Methods

3.1

Study Design

The study design involved two phases. Phase I was qualitative and designed to define a
reference standard and develop a rubric for the assessment of clinical development
project management offices (PMOs). Phase II was quantitative and designed to perform
an initial assessment of ability of the rubric to assess a comparator company’s
conformance with the reference standard.
3.2
3.2.1

Phase I: Reference Standard and Rubric Development
Questionnaire Development

Phase I began with the development of a pilot questionnaire with six, open-ended
questions. It was tested on 10 people from Company “A” and revised for a final set of 14
open-ended questions. The final questionnaire can be found in Section 8.2.2.
3.2.2

Sample Group

Following the development of the questionnaire, a sample group of respondents were
identified from three sources: 1) LinkedIn (Sunnyvale, CA) using the search term “project
management” 2) personal network referrals through the last question of the survey (“Do
you have any network contacts you can share in assisting with this research?”), and
3) Program and Portfolio Management (PPM) (New York, NY) Conference messaging
platform Bizzabo.
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3.2.3

Company Metrics

The companies for which the sample respondents were employed were evaluated on
four metrics to establish cutoffs for company size: 1) number of full-time employees,
2) revenue (US$), 3) profitability, and 4) drug pipeline (count). The number of
employees needed to qualify as a large company was defined as >10,000, medium as
1,000-9,999, and small as <1,000. The revenue amount needed to qualify as a large
company was defined as >$10B, medium as $1B – $10B, and small as <$1B. The
profitability size designation for a large company was defined as “Yes”, for medium was
“Either” (meaning either Yes or No), and for small was “No”. The drug pipeline needed to
qualify as a large company was defined as >20, for medium as 10 – 20, and for a small
company as <10. Company size classification criteria are provided in Table 3.
Table 3: Company size classification
Number of employees
Revenues
Profitability (y/n)
Drug Pipeline

Large
>10K
>$10B
Y
>20

Medium
1K – 10K
$1B – $10B
?
10 - 20

Small
<1K
<$1B
N
<10

The companies were assigned a unique identifier because permission was not
requested to use their company name for this study. To further aid maintaining
anonymity, exact metrics obtained from Yahoo! Finance (New York, NY) were rounded.
The mid-sized company with the largest number of potential respondents (41 people)
was selected as the comparator company. Personnel at the comparator company were
not contacted in Phase 1, but reserved for Phase II of the study.
3.2.4

Data Collection

An introductory e-mail message was sent to the potential pool of respondents to provide
background regarding the interviewer and the desired outcome, as well as a request to
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schedule a meeting to conduct the interview. One-hour interviews were conducted with
the respondents from March to May 2017. Data were captured during the interviews by
handwritten notes and post-meeting transcribed into a word processing document.
3.2.5

Data Cleaning

Raw data captured in the word processing document were converted to a spreadsheet
and subsequently cleaned by correcting spelling errors, spelling out abbreviations and
removing duplicate entries (deduplication). Following a consistency check for correct
project management context, high frequency words were identified by requiring that the
word or term must have occurred greater than 10 times in the raw data. False positives
(i.e., terms included in the results erroneously, such as “that” and “what” being returned
for the term “hat”) were removed (Figure 2 and Figure 3).

Figure 2: Data collection through reference standard development
Funnel structure depicting the process for reference standard development, starting with total
words from interview raw data being narrowed to high frequency words, and then classified into
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categories and subcategories to develop the final reference standard definition (denoted by the
red band).

Figure 3: Data cleaning and analysis process
Diagram depicting the process for data cleaning (from collection, data entry, deduplication to
consistency check) and data analysis (categorization).

3.2.6

Data Analysis

Analysis involved grouping high-frequency words into categories, sub-categories and
sub-sub categories, terms and attributes (the classification scheme outline and
definitions can be found in Section 8.1). These groupings were reviewed holistically for
consistency and correct categorical context (Figure 3).
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3.2.6.1 Statistical Analysis
To evaluate whether there was a difference in results based on company size, the data
analysis tool in Microsoft Excel 2013 (version 15.0, Redmond, WA) for an ANOVA: TwoFactor without Replication statistical analysis was used.
3.2.7

Reference Standard and Rubric Development

The reference standard was developed by applying a cutoff to the high frequency words.
The numbers for the highest frequency word in each of the four top level categories were
totaled, then divided by four (for the number of categories), and subsequently divided by
four again to separate into quartiles, and then rounded to the nearest whole number.
This method was selected over the use of the absolute count of the term in order to filter
out terms that fell in the bottom quartile. The high frequency words meeting the cutoff
became the terms that comprised the reference standard.
The rubric was developed by creating actionable descriptions (i.e., attributes) of the
terms in the reference standard. The descriptions were taken from the Phase I
interviews.
3.3

Phase II: Rubric Evaluation and Comparator Company Recommendations

The Phase II objectives were to evaluate the rubric and make recommendations for how
a comparator company could achieve the reference standard.
3.3.1

Questionnaire Development

The rubric developed in Phase I was converted into a Likert scale questionnaire which
asked to what degree the respondent felt each attribute was being practiced at their
company on a five-point scale (Strongly Disagree [1], Disagree [2], Neither [3], Agree [4],
or Strongly Agree [5]).
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3.3.2

Sample Group

During Phase I (Section 3.2.2), the mid-sized company with the largest potential pool of
respondents was reserved for Phase II. A mid-size company was thought to be a
suitable comparator company as it would incorporate elements of both large and small
companies.
3.3.3

Data Collection

A LinkedIn message was sent to the potential pool of respondents introducing the
objective of the study and a link to the questionnaire in SurveyMonkey® (San Mateo,
CA; Section 8.2.3). The message was sent and all responses were completed in
April 2018.
3.3.4

Data Analysis

An average company was defined as a company performing at its sizing class, which is
arbitrarily set with baselines that were neither too high nor low. To translate into a
measurable metric on the Likert scale 5-point scale, numeric results from each top level
cat average was totaled and >3.0 cutoff was set which is the mean of a 5-point scale.
The cut-off was also required to evaluate the comparator company after the survey was
conducted to set performance baselines for activities being/not being practiced.
4

Results

4.1

Phase I: Reference Standard and Rubric Development

The objectives of Phase I were to develop a reference standard and associated rubric
for the assessment of clinical development PMOs.
4.1.1

Response Results

A total potential pool of 127 respondents was identified from three sources: 1) LinkedIn
(n=79), 2) referrals (n=29), and 3) Project and Portfolio Management (PPM) conference
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messaging platform Bizzabo (n=19). Of the 127 potential respondents contacted,
23 people expressed interest and received a copy of the final questionnaire comprised of
14 questions. Seventeen of 23 completed the questionnaire with two (3%) from LinkedIn,
eleven (38%) from referrals, and four (21%) from Bizzabo. The response rate was 12%,
65%, and 24% for LinkedIn, referrals, and Bizzabo, respectively. The overall response
rate was 13% (Table 4). This response rate was lower than what was previously
reported in a study where surveys of individuals had an average response rate of 53%,
while surveys of organizations had an average response rate of 36% (12).
Table 4: Participant pool, respondents, and overall percent per platform
Platform

Potential Pool

LinkedIn
Referrals
PPM Bizzabo
Total

4.1.2

79
29
19
127

Actual
Respondents
2
11
4
17

Response %

Overall %

3%
38%
21%
13%

11.76%
64.71%
23.53%
100%

Company Metrics

The 17 respondents were from 15 companies, with three respondents from the same
company. The 15 companies were evaluated based on the criteria set in Section 3.2.3,
with four classified as large, five as medium and seven as small (Table 5).
Table 5: Number of responses by company
Company size
Large
Medium
Small
Total

Total number of interview
respondents
6
4
7
17

Total number of companies
4
4
7
15

Source: Yahoo!Finance, 2017 (13)

Evaluating each company’s revenue and drug pipeline against the number of full-time
employees (FTE) provides metrics to measure their performance relative to their peers.
For example, of the four companies classified as large, Companies 1 and 2 have a
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revenue/FTE value of $600K each, while Companies 3 and 4 have a revenue/FTE value
of $1M each, implying that Companies 3 and 4 are performing better relative to
Companies 1 and 2. The pipeline/FTE ratio of Company 1 is 0.0006, for Companies 2
and 3 are 0.001, and for Company 4 is 0.002, implying that Company 4 is performing
better than the other three companies (Table 6).
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Table 6: Company metrics of respondents
Company ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

FTE
90,000
30,000
30,000
20,000
9,000
8,000
1,000
1,000
500
300
200
100
100
100
100

Revenue
(US$)
60B
20B
30B
20B
30B
6B
500M
2B
3M
300M
NA
1M
10M
NA
NA

Profitable
Y
Y
Y
Y
Y
Y
N
N
N
Y
NA
N
N
NA
N

Drug
Pipeline
50
40
40
40
40
10
10
20
10
10
10
5
10
1
10

Size
Classification
Large
Large
Large
Large
Medium
Medium
Medium
Medium
Small
Small
Small
Small
Small
Small
Small

Respondents
3
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Revenue/
FTE (US$)
600K
600K
1M
1M
3.3M
750K
500K
2M
6K
1M
NA
10K
100K
NA
NA

Pipeline/
FTE
0.0006
0.001
0.001
0.002
0.004
0.001
0.01
0.02
0.02
0.03
0.05
0.05
0.1
0.01
0.1

Source: Yahoo!Finance 2017 (13)
FTE = full-time employees
NA = Not available
Drug Pipeline = set of drug candidates that a pharmaceutical company has under discovery or development and any given point in time.

16

4.1.3

Categorization Overview

The 17 interviews culminated in a total of 5,712 words relevant to project management
context, which were further cleaned using the method outlined in Section 3.2.5, resulting
in 540 high frequency words. The high frequency words were then grouped into four top
level categories: 1) Soft Skills, 2) Hard Tools, 3) Organizational Structure, and 4) PMO
Components. Each of the categories had multiple sub-categories and sub-subcategories
(Table 7).
The Soft Skills category had 14 sub-categories (alphabetical, number of terms per
category indicated in parenthesis after the term): Collaboration (8), Communication (54),
Experience (9), Flexibility/Versatility (12), General (9), Humility (1), Innovative (6), Looks
after best interests of project (1), Reading People (3), Relationship Building (6), Strategy
(14), Tact and Diplomacy (2), Team Management (8), and Trust (9). The 54 terms in
Communication were divided into four sub-subcategories: General (24), Project
Management (PM) Specific (20), Processes (3) and Team Management (7). The Soft
Skills sub-categories included in the reference standard were Communication (the three
sub-subcategories of General, PM Specific and Team Management), Experience,
General and Strategy.
The Hard Tools category had two sub-categories: Processes (128) and Technology (29).
The 128 terms in Processes were divided into 10 sub-subcategories: Budget (32),
Contracting (1), Deliverables Management (8), General (10), Lifecycle Management (2),
Matrices (4), Meeting Management (16), Resource Management (15), Technology
Strategy (5), Timelines (18), and Training (17). The 29 terms in Technology were divided
into nine sub-subcategories: Collaboration (2), Communication (5), Dashboards (6),
Deliverables Management (1), Document Control (6), Hardware (1), Lifecycle
Management (1) PPM (2), and Timelines (5). Although Timelines are found in both the
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Processes and Technology sub-categories, they are defined differently, where Timelines
in Processes is defined as creating timelines and Timelines in Technology is defined as
a tool, such as a Gantt chart. The Hard Tools sub-category Processes included in the
reference standard were Budget, Deliverables Management, Meeting Management,
Resource Management, Timelines, and Training. There were no Technology subcategories included in the reference standard.
The Organizational Structure category had 10 sub-categories: Alliance Management
(14), Constraints (14), Culture (6), Efficiencies (14), General (12), Governance (34),
Integration (4), Matrix Organization (26), Silo Organization, (3), and Transparency (2).
The 14 terms in Constraints were divided into two sub-subcategories: General (9) and
Turnover (5). The 26 terms in Matrix Organization were divided into three subsubcategories: General (8), PM Role (7), and Teams (11). The Organizational Structure
sub-categories included in the reference standard were Alliance Management,
Efficiencies, General, Governance, and the Teams sub-subcategory of Matrix
Organization.
The PMO Components category had five sub-categories: Alignment (13), General (5),
Methodologies (17), PM Role (62), and Portfolio Management (6). The 62 terms in PM
Role were divided into four sub-subcategories: General (44), Leadership (2), Strategic
(11), and Tactical (5). The PMO Components sub-categories included in the reference
standard were Alignment, Methodologies, and PM Role (with two sub-subcategories
General and Strategic).
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Table 7: Categorization overview (alphabetical)
Category (n)
Soft Skills (14)

Sub-categories (n)
Collaboration (8)

Sub-subcategories (n)

Communication (54)

N=4: General (24), PM Specific (20),
Processes (3), Team Management (7)

Experience (9)
Flexibility/Versatility (12)

Hard Tools (2)

General (9)
Humility (1)
Innovative (6)
Looks after Best Interests of
Project (1)
Reading People (3)
Relationship Building (6)
Strategy (14)
Tact & Diplomacy (2)
Team Management (8)
Trust (9)
Processes (128)

Technology (29)

Organizational
Structure (10)

PMO
Components
(5)

N=10: Budget (32), Contracting (1),
Deliverables Management (8), General (10),
Lifecycle Management (2), Matrices (4),
Meeting Management (16), Resource
Management (15), Technology Strategy (5),
Timelines (18), Training (17)

N=9: Collaboration (2), Communication (5),
Dashboards (6), Deliverables Management (1),
Document Control (6), Hardware (1), Lifecycle
Management (1), PPM (2), Timelines (5)

Alliance Management (14)
Constraints (14)
Culture (6)
Efficiencies (14)
General (12)
Governance (34)
Integration (4)
Matrix Organization (26)
Silo Organization (3)
Transparency (2)
Alignment (13)
General (5)
Methodologies (17)
PM Role (62)

N=2: General (9), Turnover (5)

N=3: General (8), PM Role (7), Teams (11)

N=4: General (44), Leadership (2), Strategic
(11), Tactical (5)

Portfolio Management (6)
*Items indicated in Bold were included in the reference standard definition
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4.1.3.1 Overview of Categories
When looking at the aggregated results, the distribution across the four categories was
fairly even. Soft skills and Organizational Structure were 26% each, Hard Tools and
PMO components were 29% and 19%, respectively (Figure 4).
To determine whether company size affected the distribution, the four categories were
analyzed by company size (Section 4.1.2). The category distribution for large companies
was 21% for Soft Skills, 35% for Hard Tools, 26% for Organizational Structure, and 18%
for PMO Components. The category distribution for medium companies was 25% for
Soft Skills, 37% for Hard Tools, 18% for Organizational Structure and 20% for PMO
Components. The category distribution for small companies was 32% for Soft Skills,
19% for Hard Tools, 28% for Organizational Structure and 21% for PMO Components.
ANOVA: Two-Factor without Replication statistical analysis of these results found no
statistical significance, with a p-value of 0.41 (Figure 4 and Table 8). Thus, results were
only analyzed at the overall level, not by company size.

Figure 4: Top level category distribution overall and by company size
Top level category distribution overall and by company size (large, medium, and small). ANOVA
analysis found no statistically significant difference in the distribution based on company size
(p-value = 0.41).
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Table 8: Statistical analysis of top level category distribution by company size
ANOVA: Two-Factor Without Replication
SUMMARY
Count
Sum
Soft Skills
3
78
Hard Tools
3
91
Organizational
3
72
Structure
PMO Components
3
59
Large
4
100
Medium
4
100
Small
4
100
ANOVA
Source of
SS
df
Variation
Rows 176.6667
3
Columns
0
2
Error 317.3333
6
Total
494
11

Average
26
30.33333
24

Variance
31
97.33333
28

19.66667
25
25
25

2.333333
55.33333
72.66667
36.66667

MS

F

P-value

F crit

58.88889
0
52.88889

1.113445
0

0.414591
1

4.757063
5.143253

SS: Sum of squares
Df: Degrees of freedom
MS: Mean squares
F: F Statistic, variance of the group means (Mean Square Between)/mean of within group variances (Mean
Squared Error)
F-crit: Probability value can occur (p value less than alpha)

The overall category distribution for three of the top level categories (Soft Skills, Hard
Tools, and PMO Components) had a single sub-category distinctly larger than the rest of
their sub-categories, while Organizational Structure showed a more even distribution
across sub-categories. The distribution of sub-categories (from highest to lowest) for
Soft Skills was 38% for Communication, 10% for Strategy, 8% for Flexibility/Versatility,
6% each for Collaboration, Experience, General, Team Management and Trust, 4% for
Innovative and Relationship Building, 2% for Reading People and 1% each for Humility,
Looks after Best Interests of the Project and Tact and Diplomacy. The Hard Tools subcategory distribution was 82% for Processes and 18% for Technology. Organizational
Structure sub-category distribution was 26% for Governance, 20% for Matrix
Organization, 11% each for Alliance Management, Constraints, Efficiencies, 9% for
General, 5% for Culture, 3% for Integration, 2% each for Silo Organization and
Transparency. PMO Components sub-category distribution was 60% for PM Role, 17%
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for Methodologies, 13% for Alignment, 6% for Portfolio Management, and 5% for
General (Figure 5).

Figure 5: Sub-category distribution by top level category overall
The sub-category distribution overall for three of the top level categories (Soft Skills, Hard Tools and PMO
Components) had a single sub-category distinctly larger than the rest of their sub-categories while the subcategories for Organizational Structure were more evenly distributed
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4.1.4

Reference Standard Definition

The objective of the reference standard definition was to create a rubric that could be
used by pharmaceutical companies to evaluate and improve clinical development project
management performance. The initial list of categories (including sub and subsubcategories) totaled 65. Definition of each category with three to seven attributes
would have produced a reference standard with hundreds of attributes, which was
deemed too large to be usable. To produce a more manageable reference standard, a
cutoff of ≥ 6 (Section 3.2.7) was applied resulting in 21 categories (indicated in bold in
Table 7). These categories were then defined using words taken directly from the
respondent interviews in Phase I to produce a total of 72 attributes (Section 8.3.2).
Use of the cutoff of ≥ 6 (Section 3.2.7) resulted in certain terms with higher absolute
values not being included. For example, in the Soft Skills category, Flexibility/Versatility
had a total count of 12 terms. However, when distributed by company size, they all fell
into the bottom quartile: large (5), medium (2), and small (5), and so did not reach the
cut-off (>6). Experience, on the other hand, had a total of 9 terms. The company size
distribution was large (0), medium (8), and small (1). The medium count of eight fell
above the >6 cut-off (i.e., outside the bottom quartile), so was included in the reference
standard definition. The same was applied to the remaining top level categories (Hard
Tools, Organizational Structure, and PMO Components). The individual categories had
variable number of sub-subcategories and some sub-categories with additional context
required a third level of categorization. Raw data for the word counts, organized by
category (and sub and sub-sub) and company are provided in Table 19.
4.1.5

Reference Standard Rubric

The reference standard definition (72 attributes) was then converted into 72 actionable
statements, i.e., the reference standard rubric, Section 8.3.2).
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4.2

Phase II: Rubric Evaluation and Comparator Company Recommendations

The Phase II objectives were to evaluate the rubric and make recommendations for how
a comparator company could achieve the reference standard.
4.2.1

Response Results

Of the total potential pool of respondents of 41 people contacted via LinkedIn, 22 people
expressed interest and received a copy of the 5-point Likert scale survey comprised of
72 questions (see Section 3.3.1). Of the 22 that expressed interest, six respondents
completed the survey (27% response rate). For Soft skills, which had 22 attributes, all of
the responses were above the 3.0 cut-off, with the mean (median) of the six responses
ranging from 3.6 – 4.5 (3.5 – 4.5). None of the six respondents Strongly Disagreed.
There was one Disagree response each for three attributes (information sharing is
concise, information sharing is precise, and PMs are effective at ensuring issues are
appropriately shared across teams). Hard Tools had 24 attributes, with the mean
(median) of the six responses ranging from 2.5 – 4.0 (2.5 – 4.0). Four of the Hard Tools
attributes were below the 3.0 cut-off. Four of six respondents Strongly Disagreed with
four attributes (Organization Tracks Actuals Against Budget, Team Members are Kept to
a Minimum, PM Training Leverages Project Management Body of Knowledge [PMBOK],
and Organization Provides Just-in-Time [JIT] Training [i.e., relevant training is provided
just before needed]). There were Disagree responses for all but three attributes.
Organizational Structure had 14 attributes, with the mean (median) of the six responses
ranging from 2.8 – 3.8 (3.0 - 4.0). All of the responses for Organizational Structure
attributes were above the 3.0 cut-off. None of six respondents Strongly Disagreed.
Neither agree nor disagree responses accounted for a majority of responses. PMO
components had 11 attributes, with the mean (median) of the six responses ranging from
2.5 – 4.2 (2.5 – 4.0). All but one of the responses for PMO components attributes were
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above the 3.0 cut-off. One of six respondents Strongly Disagreed with one attribute
(organization leverages PMBOK practices). There were four Disagree responses for
three attributes (PMs ensure portfolio and product strategies are developed, PMs help
teams to think strategically, organization leverages PMBOK practices, and PMs assist in
establishing agreed upon product development plans).
4.2.2

Data Analysis

In order to evaluate the usability of the rubric, four factors were analyzed: 1) response
rate, 2) completion rate, 3) completion time and 4) response variation. The survey
response rate was 27%, which was higher than the response rate from LinkedIn
(11.76%), lower than the response rate from referrals (64.71%) and comparable with the
response rate for the Bizzabo platform (23.53%). All of the respondents (n=6) that
started the survey, completed it. The time for completion ranged from 7:01 minutes to
51:12 minutes, with five out of six respondents’ completion times under 17 minutes. The
average completion time of all the respondents was 18 minutes, and was 11:34 minutes
if the one outlier (51:12 minutes) was excluded. Responses were varied both within each
individual respondent’s results and across respondents, i.e., no respondent answered all
statements with the same value, nor did any respondents answer all questions
identically.
In order to evaluate the performance of a comparator company relative to the
expectations of an average company (defined as a score of 3.0), the overall mean and
median values of the survey results were calculated for each of the four categories.
The mean (median) for Soft Skills was 4.8 (4.0), for Hard Tools 3.9 (3.4), Organizational
Structure 3.9 (3.4) and PMO Components 4.3 (4.3) (Table 9 and Supplementary
Table 19).
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Table 9: Comparator company overall mean and median values

Mean
Median

Soft Skills

Hard Tools

4.8
4.0

3.9
3.4

Organizational
Structure
3.9
3.4

PMO
Components
4.3
4.3

The comparator company, a mid-sized company identified in Phase I and reserved for
Phase II testing (Section 3.2.3) had 7,300 employees with a revenue of $12B, and was
profitable with 17 products in the pipeline (Table 10).
Table 10: Comparator company size evaluation
Number of employees
Revenues
Profitability (y/n)
Pipeline

Medium
1K – 10K
$1B – $10B
Y or N
10 - 20

Comparator Company
7,300
$12B
Y
17

Source: Yahoo!Finance 2017 (13)

5

Discussion

The objectives of Phase I were to define a reference standard and develop an
associated rubric for the assessment of clinical development PMOs. The Phase II
objectives were to evaluate the rubric and make recommendations for how a comparator
company could achieve the reference standard.
5.1.1

Phase I: Reference Standard and Rubric Development

Each of the four top level categories had themes. Soft Skills had three themes:
Communication, Strategy, and Experience. Hard Tools themes centered on Processes,
with sub-themes of Budget, Deliverables Management, Meeting Management, and
Resource Management, Timelines, and Training. Although Timelines are found in both
subcategories (Processes and Technology), they are defined differently, where
Timelines in Processes is defined as creating timelines and Timelines in Technology is
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defined as a tool, such as a Gantt chart. Organizational Structure had themes around
Governance, Efficiencies, and Teams. PMO Components included themes around the
PM Role, Methodologies and Alignment (Figure 5).
Although Soft Skills had three themes (i.e., Communication, Strategy, and Experience),
the theme of Communication was dominant, representing more than one-third of the
attributes (38%). This reveals not only the need for good communication, but how easily
poor communication can become an issue. The reference standard provides best
practices needed to effectively communicate by specifying the attributes required, e.g.,
direct, concise, and precise.
The Hard Tools themes focused on processes, accounting for 82% of the terms for this
category, highlighting the difficulty in achieving good processes. The processes
necessarily incorporate technology (which is important to meet specific needs), however,
technology alone cannot meet all the needs. Therefore, a focus on processes for
budgeting, training, and resource management are important as best practices.
The Organizational Structure themes were Governance (26%), Efficiencies (11%) and
Teams as part of a Matrix Organization (20%). The data suggest that Governance is
important because of its role in decision making. Therefore, a focus on Governance
ensures that the organization has specific decision making and escalation pathways.
Efficiencies focused on reducing the amount of time that processes required and on
ensuring that “trains run on time”. Data on Teams as part of Matrix Organization focused
on the need for teams to manage the project (called “project teams”).
The PMO Components category had themes around the PM Role (62%), Methodologies
(17%) and Alignment (13%). The data suggest that an important component to a PMO is
the organization’s understanding of what the project manager does and how their role
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fits into the overall team structures. Methodologies focused on the importance of
leveraging the Project Management Body of Knowledge (PMBOK) from the Project
Management Institute (PMI). Alignment focused on ensuring that the organization was
internally aligned, and highlighted the importance of establishing agreed upon goals and
objectives.
The results reveal that the four top level categories can be grouped into two
designations: “individual” and “organizational”. Soft Skills and Hard Tools fit into the
“individual” designation because these categories are performed by an individual.
Organizational Structure and PMO Components fit into the “organizational” designation
because they are performed at the company level. For example, General
Communication in Soft Skills consists of attributes of concise and direct communication.
Although that could be considered an organizational designation (since all-around
communication is important), the skill must first occur at an individual level in order for
communication to impact the level of the organization. Organizational Structure includes
Governance, which can only occur at a company level.
5.1.2

Phase II: Rubric Evaluation and Comparator Company Recommendations

The Phase II objectives were to evaluate the rubric and make recommendations for how
a comparator company could achieve the reference standard.
The evaluation of rubric usability involved four factors: 1) response rate, 2) completion
rate, 3) completion time and 4) response variation. The response rate was 27%, which is
on the higher end of what was seen in Phase I for non-referrals (none of the
respondents were referrals). All of the respondents that started the survey, completed it,
indicating that they were not deterred by the survey despite it being comprised of 72
questions. Five out of six respondents required less than 12 minutes to complete the
survey, indicating that the time required for completion was not onerous. There were
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variations in the responses selected (both individually and across the sample group),
indicating that respondents read the statements before responding.
The rubric was used to evaluate a comparator company’s performance relative to the
reference standard and whether that aligned with its performance relative to its peers.
Based on the reference standard, the comparator company was ranked as performing
above average in all Soft Skills attributes. Four attributes in Hard Tools were identified
as needing additional work: 1) clear processes for adding resources and/or changing
priorities, 2) organization-wide timeline templates with standard durations, 3) PM training
to leverage PMBOK, and 4) organization-provided JIT training. One attribute each in
Organizational Structure (the organization has the right-sized infrastructure in place),
and PMO Components (the organization leverages PMBOK practices) were also
identified as needing additional work.
In theory, the reference standard rubric should reflect whether the performance of the
company is at, above or below its performance measures relative to its peers. Based on
the company metrics established in Section 4.1.2 and the mean and median analysis in
Section 4.2.2, the comparator company appears to be doing incrementally better than
average mid-sized companies, which is consistent with the Phase II results in Table 10.
5.1.3

Limitations and Future Research

As with all research, there are limitations to this study. One example is geographical, as
all the respondents were solely from the West coast of the United States (US).
Therefore, it is unknown whether this information will hold true for other regions of the
US and/or for other countries. Both Phase I and Phase II sample groups were small so
the findings could change with larger cohorts. For example, “Soft Skills’, Team
Management” doesn’t appear for small size companies. This might be an artifact of the
small sample size or it might be replicated in a larger cohort and thus identified as an
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area worth further exploration. Finally, the study was not able to comprehensively
evaluate and/or validate the accuracy and precision of the rubric, company metrics
definition, and the cut-offs. As the ultimate goal is to decrease the amount of time for
clinical development in pharmaceutical companies, one way to determine whether the
reference standard is causative rather than solely correlative would be to measure
clinical development time pre- and post-implementation of the reference standard.
6

Conclusion

The objective of all projects is to be on time, on budget, and within scope. In clinical
development, that means safety and effectiveness within the intended population as
quickly as possible. Average time to market for a drug in development is ten to fifteen
years, and of that, seven to ten years are spent in clinical development. While a general
project management standard for PM methodologies and techniques is outlined in the
PMBOK by the PMI and best practices outlined for many industries, there are no current
publications supporting project management in clinical development nor current
performance measures based on clinical development project management best
practices. Hence there is a need for defining best practices for clinical development
project management. To meet this need, Phase I defined a reference standard and
actionable guide (rubric) for the assessment of clinical development PMOs. The Phase II
evaluated the usability of the rubric as a tool for identifying areas of strength and
opportunity for clinical development project management best practices. Although further
work is necessary, this research sets the foundation for more effectively leveraging
clinical development project management to expedite bringing products to patients.
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Appendix

8.1

Reference Standard Classification Scheme

The reference standard classification scheme uses the following hierarchy:
•

8.2
8.2.1

Category – highest level in the scheme, total of four
o Sub-category – groupings within categories
Sub-subcategory – groupings within sub-categories
• Term – actual word taken from Phase I interviews.
Reference Standard at this level (subset of total items).
o Attribute – Description of term created using
information taken from Phase I interviews. Rubric at
this level (limited to terms in Reference Standard).
Interview Questions
Study Design

Questions:
1. What does the Center of Excellence mean to you?
2. What best practices/strategies do you employ to successfully complete your
tasks?
3. What pitfalls do you avoid & how?
4. Tell me a little bit about your career path, how did you move into PM?
5. Based on your current experience in the field, what have you done differently to
be more productive or to stay ahead of the game?
6. Do you have any internal or external contacts you can share in regards to
assisting with my COE Research?

8.2.2

Phase I

Questions:
1. What does a Project Management Center of Excellence mean to you?
2. What PPM best practices/strategies have you personally observed (or perhaps
used) that were helpful in teams/work streams to completing tasks and/or
deliverables?
3. Are there specific pitfalls you have observed when trying to implement
project/portfolio practices at companies you’ve been a part of? Some pitfalls may
be situations such as: Undefined goals, scope changes, lack of accountability,
lengthy decision-making processes, issues with change management, or lack of
communication.
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4. What difficulties with interpersonal interactions in team dynamics have you
observed and were there specific tools and techniques you have seen project
managers apply to avoid or resolve difficulties?
5. Regarding the PM’s you’ve worked with, are there certain types of backgrounds
or characteristics that the most effective PM’s share?
6. Based on your current experience in the field, what have you done differently to
be more productive or to stay ahead of the game?
7. What has your company done differently to be ahead in terms of innovation and
creativity in PPM?
8. What best practices/strategies/toolkits does your company leverage to
successfully complete tasks?
9. What are some PPM best-practices you’ve experienced with previous
employers?
10. What are best-practices you noticed were different (yet positive) from standard
practices at your current employer?
11. Based on your industry experience, what do you feel companies do well in
regards to PPM? How do they do those things?
12. What and how would you like to do things differently in a Project Management
Office if given the opportunity?
13. Do you have any internal or external PPM contacts you would be willing to share
for participation in this survey?
14. What tools, best practices, systems or rules would you include in a Project
Management Center of Excellence?

8.2.3

Phase II

Likert-scale Survey Questions:
Soft Skills
1.
2.
3.
4.
5.
6.
7.
8.

Communications in my organization are direct and to the point without being rude
Messages are tailored to the audience
Messages are conveyed with humility
Humor is used appropriately in communications
Information is shared in a timely manner
Information sharing is concise
Information sharing is precise
PMs are effective at communicating information internally and externally (e.g.,
teams, management, outside company, etc.)
9. PMs are effective at communicating constraints and potential solutions
10. PMs are effective at ensuring issues are appropriately shared across teams
11. PMs are able to effectively share the pros and cons of mitigations
12. PMs have real-time, high level knowledge of the project
13. PMs are able to effectively communicate bad news
14. PMs regularly check in with stakeholders
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15. PMs leverage multiple communication methods effectively to obtain responses
from team members
16. PMs check the "pulse" of the team during meetings
17. PMs are able to guide team meeting discussions so they remain constructive and
productive
18. Programs are prioritized at a portfolio level
19. Trade-off decisions factor in both program and portfolio levels
20. Competitive intelligence is used to inform portfolio and product strategy
21. Organization provides opportunities for both formal training and hands on
experience (including feedback)
22. Soft skills are highly valued

Hard Tools
23. My organization has a current annual budget and five-year plan
24. Projects are funded based on probability of success at the portfolio level
25. Organization tracks actuals against budget
26. Cost modeling & forecasting is used to inform budget and five-year plan
27. Projects have clearly identified deliverables
28. Responsibility for project deliverables is clearly identified
29. Delivery of project deliverables is tracked against internal and external
commitments
30. Clear process for escalating potential delays in meeting project deliverables per
internal and external commitments
31. Team members are kept to a minimum
32. Meeting agendas and minutes are developed and distributed in a timely manner
33. Action Item, Decision and Issues (ADI) logs are maintained
34. Risks are documented and evaluated
35. Resource needs are identified
36. Regular reviews of needed vs available resources are conducted
37. Clear process for adding resources and/or changing priorities to reduce workload
in the event there are not enough resources to meet the need
38. Timelines are developed and maintained
39. Timeline projected vs actuals tracked (particularly for critical path)
40. Clear escalation process if timelines exceed agreed upon thresholds
41. Organization has timeline templates with standard durations
42. Organization has the ability to conduct scenario planning
43. Timelines are used to decrease overall development duration
44. Organization provides training for team members including team
tools/processes/best practices, e.g., critical path understanding
45. PM training leverages Project Management Body of Knowledge (PMBOK)
46. Organization provides Just-in-Time (JIT) training (i.e., relevant training is
provided just before needed)
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Organizational Structure
47. Organization has clear escalation pathways
48. Organization has clear decision making pathways
49. Decisions in my organization are unambiguous and specific
50. Decisions in my organization are documented and readily retrievable
51. Cross-functional teams make product development faster, cheaper, and/or higher
quality
52. Cross-functional teams in my organization have a clear purpose and scope
53. Team members have clear understanding of their role
54. Organizational best practices are established which are appropriate to the
product development phase
55. Organizational best practices are leveraged to quickly set up teams, tools, and
processes
56. Organizational best practices lead to decreased product development time
57. Organizational best practices are continuously improved through process
improvement initiatives
58. Organization effectively leverages partnerships to extend resources and/or
capabilities
59. Organization effectively leverages partnerships to share and/or reduce risks
60. Organization has the right-sized infrastructure in place to support projects

PMO Components
61. Does your organization have a formal PMO
62. Roles are clearly defined for PM and team members
63. PM's scope is cross-functional
64. PMs ensure teams meet organizational objectives/goals
65. PMs ensure portfolio and product strategies are developed
66. PMs help teams think strategically
67. Organization has and uses established methodologies, processes, tools, and
training
68. Organization leverages PMBOK practices
69. PMs assist in establishing agreed upon goals and objectives
70. PMs assist in establishing agreed upon product development plans
71. PMs track organizational progress against goals and objectives
72. PMs escalate issues as appropriate
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8.3

Reference Standard and Rubric Development

8.3.1

Reference Standard

Table 11: Soft Skills Terms
Communication:
General

Communication:
PM Specific

Direct

Needs to be able
to communicate
at all levels
internally and
externally ("PM
and Project Lead,
cross-department,
can communicate
at all ends, up
and outward,
bottom up to top
down,
executives")
Effectively able to
communicate
constraints and
potential solutions
(Communicates
why things can't
be done, if can't
be done ask for
more resources)
to Management
Communicates
issues across
team

Flexibility

Humble

Sense of humor
Timeliness
("quick")
Concise
Precise

Communication:
Team
Management
Escalation tactics
for obtaining a
response from
team members
(Face to Face,
telecom)

Strategy

Experience

General

Prioritization
at program
level

Combination
of formal
training and
hands on
experience
with feedback

Soft
skills are
more
important
than
hard
skills

Take "pulse" at
team meetings

Trade-offs at
program and
portfolio level

Experience

Stop/Control
conversation in
meetings

Leveraging
Competitive
intelligence to
inform
strategy

Show pros/cons
of mitigations
Real-time
knowledge of
project, high level
Able to
communicate bad
news
Regularly checkins with
stakeholders
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Table 12: Hard Tools Terms
Processes:
Budget

Processes:
Deliverables
Management
Clear
identification
of project
deliverables

Processes:
Meeting
Management
Keep number
of team
members to a
minimum

Processes:
Resource
Management
Identification
of resource
needs

Processes:
Timelines

Processes:
Training

Develop &
maintain
timelines

Portfolio of
Projects
funded
based on
probability
of success

Clear
identification
of who's
responsible for
what project
deliverables

Regular
evaluation of
resource
needs relative
to available
resources

Track actuals
against
projected,
particularly for
critical path

Track
actuals
against
budget

Track project
deliverables
against
internal and
external
commitments

Meeting
agendas and
minutes:
developed
and
distributed in a
timely manner
ADI logs
maintained

Have training for
team members
which includes team
tools/processes/best
practices, e.g.,
critical path
understanding
PM training
leverages Project
Management Body
of Knowledge
(PMBOK)

Mechanism
for decision
making if
more
resources are
required than
available to
either 1) add
more staff or
2) change
priorities to
reduce
workload

Mechanism
for escalating
if timelines
exceed
agreed upon
thresholds

Cost
modeling (to
inform
budget)

Mechanism for
escalating if
project
deliverables
not tracking to
meet internal
and external
commitments

Annual
budget and
five-year
plan
developed
and current

Risks
evaluated and
documented

Just in time (JIT)
training (i.e.,
conducted before
using)

Timeline
templates with
standard
durations

Ability to
conduct
scenario
planning
Timelines
leveraged to
find ways to
shorten
overall
development
duration
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Table 13: Organizational Structure Terms
Governance
Clear
communication
pathways

Clear decision
making process

Decisions are
unambiguous and
specific

Matrix
organization:
Teams
Cross-functional
teams make
product
development
faster, cheaper,
and/or higher
quality
Teams have a
clear purpose and
scope

Team members
understand their
role

Decisions are
documented &
readily retrievable

Efficiencies

Alliance
Management

General

Have established
organizational best
practices which are
right sized to the
project phase

Effectively
leverage
partnerships to
extend resources
and/or capabilities

Right-sized
infrastructure setup and in place to
support projects

Leverage
organizational best
practices to
facilitate quickly
setting up teams,
tools and
processes
Organizational
best practices lead
to decreased
product
development time
Continuously
improve through
process
improvement
initiatives

Effectively
leverage
partnerships to
share and/or
reduce risks

Table 14: PMO Components Terms
PM Role: General
Role is clearly defined
both for PM and other
roles with which the PM
interacts
Scope is crossfunctional
Responsible for
ensuring team meets
organizational
objectives/goals
PM Role: General

PM Role: Strategic
Ensures portfolio and
product strategy
developed
Helps teams think
strategically

Methodologies
Established
methodologies,
including processes,
tools and training
Methodologies
appropriately leverage
PMBOK practices

Alignment
Help establish agreed
upon goals and
objectives
Helps establish agreed
upon product
development plan
Tracks progress against
goals and objectives
Escalates issues as
appropriate
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8.3.2

Rubric Development

Table 15: Soft Skills Attributes
Communication:
General

Communication:
PM Specific

Communication:
Team
Management
PMs leverage
multiple
communication
methods
effectively to
obtain responses
from team
members

Strategy

Experience

General

Communications
in my organization
are direct and to
the point without
being rude

PMs are effective
at communicating
information
internally and
externally (e.g.,
teams,
management,
outside company,
etc.)

Programs
are
prioritized at
a portfolio
level

Organization
provides
opportunities
for both
formal
training and
hands on
experience
(including
feedback)

Soft skills
are highly
valued

Messages are
tailored to the
audience

PMs are effective
at communicating
constraints and
potential
solutions

PMs check the
"pulse" of the
team during
meetings

Messages are
conveyed with
humility

PMs are effective
at ensuring
issues are
appropriately
shared across
teams

PMs are able to
guide team
meeting
discussions so
they remain
constructive and
productive

Trade-off
decisions
factor in both
program and
portfolio
levels
Competitive
intelligence
is used to
inform
portfolio and
product
strategy

Humor is used
appropriately in
communications

PMs are able to
effectively share
the pros and
cons of
mitigations
PMs have realtime, high level
knowledge of the
project
PMs are able to
effectively
communicate
bad news
PMs regularly
check in with
stakeholders

Information is
shared in a timely
manner
Information
sharing is concise
Information
sharing is precise
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Table 16: Hard Tools Attributes
Processes:
Budget

Processes:
Deliverables
Management
Projects have
clearly
identified
deliverables

Processes:
Meeting
Management
Team
members are
kept to a
minimum

Processes:
Resource
Management
Resource
needs are
identified

Processes:
Timelines

Processes: Training

Timelines are
developed
and
maintained

Projects are
funded based
on probability
of success at
the portfolio
level

Responsibility
for project
deliverables is
clearly
identified

Regular
reviews of
needed vs
available
resources are
conducted

Timeline
projected vs
actuals
tracked
(particularly
for critical
path)

Organization
tracks actuals
against
budget

Delivery of
project
deliverables is
tracked
against
internal and
external
commitments

Meeting
agendas and
minutes are
developed
and
distributed in
a timely
manner
Action Item,
Decision and
Issues (ADI)
logs are
maintained

Organization
provides training for
team members
including team
tools/processes/best
practices, e.g., critical
path understanding
PM training
leverages Project
Management Body of
Knowledge (PMBOK)

Clear process
for adding
resources
and/or
changing
priorities to
reduce
workload in
the event
there are not
enough
resources to
meet the
need

Clear
escalation
process if
timelines
exceed
agreed upon
thresholds

Cost
modeling &
forecasting is
used to
inform budget
and five-year
plan

Clear process
for escalating
potential
delays in
meeting
project
deliverables
per internal
and external
commitments

My
organization
has a current
annual
budget and
five-year plan

Risks are
documented
and evaluated

Organization
provides Just-in-Time
(JIT) training (i.e.,
relevant training is
provided just before
needed)

Organization
has timeline
templates
with standard
durations

Organization
has the ability
to conduct
scenario
planning
Timelines are
used to
decrease
overall
development
duration
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Table 17: Organizational Structure Attributes
Governance
Organization has
clear escalation
pathways

Organization has
clear decision
making pathways

Decisions in my
organization are
unambiguous and
specific
Decisions in my
organization are
documented and
readily retrievable

Matrix
organization:
Teams
Cross-functional
teams make
product
development
faster, cheaper,
and/or higher
quality
Cross-functional
teams in my
organization have
a clear purpose
and scope
Team members
have clear
understanding of
their role

Efficiencies

Alliance
Management

General

Organizational
best practices are
established which
are appropriate to
the development
phase

Organization
effectively
leverages
partnerships to
extend resources
and/or capabilities

Organization has
the right-sized
infrastructure in
place to support
projects

Organizational
best practices are
leveraged to
quickly set up
teams, tools, and
processes
Organizational
best practices lead
to decreased
product
development time
Organizational
best practices are
continuously
improved through
process
improvement
initiatives

Organization
effectively
leverages
partnerships to
share and/or
reduce risks

Table 18: PMO Components Attributes
PM Role: General
Roles are clearly
defined for PM and
team members

PM Role: Strategic
PMs ensure portfolio
and product strategies
are developed

PM's scope is crossfunctional

PMs help teams think
strategically

PMs ensure teams
meet organizational
objectives/goals

Methodologies
Organization has and
uses established
methodologies,
processes, tools, and
training
Organization leverages
PMBOK practices

Alignment
PMs assist in
establishing agreed
upon goals and
objectives
PMs assist in
establishing agreed
upon product
development plans
PMs track
organizational progress
against goals and
objectives
PMs escalate issues as
appropriate
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Supplementary Figures and Tables

Table 19: Term count by company identifier and top level category
Company
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Total

Soft
Skills
16
14
5
14
17
0
3
5
3
10
10
5
14
11
15
142

Hard
Tools
60
6
7
7
8
1
24
4
0
10
5
2
16
1
6
157

Organizational
Structure
33
5
9
12
6
6
5
1
14
13
6
8
11
6
2
137

PMO
Components
18
5
15
2
6
7
2
5
7
12
11
3
6
3
2
104

Total
33
5
9
12
6
6
5
1
14
13
6
8
11
6
2
540
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Figure 6a-d: Phase I term counts and reference standard definition cut-off
Top level categories by attribute and company size with the cut-off (>6) for the reference standard applied.
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Figure 7a-d: Phase II survey results (raw data)
Phase II survey responses providing assessment of company’s performance (percentage) relative to each attribute.
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Figure 8a-d: Phase II survey results (mean) and evaluation cut-off
Phase II comparator company survey results by top level categories relative to evaluation cut-off (>3.0 as indicated by the red line).
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